Absci Corporation
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Sean McClain
- Full Time Employees
- 156
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 18105 SE Mill Plain Boulevard Vancouver WA United States of America 98683
- IPO Date
- Jul 22, 2021
- CIK
- 0001672688
- Website
- absci.com
- Similar Companies
- Business
- Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Company News
Absci to Participate in Upcoming Investor Conferences
Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market
Which Healthcare Stock Is the Best Buy Right Now?
Absci to Participate in Upcoming Investor Conferences
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Absci Corporation (ABSI) Q4 2024 Earnings Call Transcript
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
Absci to Participate in the TD Cowen 45th Annual Health Care Conference
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery